Company overview
Rentschler Biopharma is a global leading CDMO specializing in full-service bioprocess development and cGMP manufacturing of high-quality biopharmaceuticals, including complex biologics and recombinant proteins. With over 50 years of experience, they offer expertise in process optimization, analytical and formulation development, and client program management across state-of-the-art facilities. Recent expansions include new production lines in Milford, Massachusetts, and buffer media manufacturing in Laupheim, Germany, to meet growing demand.
Rentschler Biopharma is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing partner serving United States & Americas. Core focus areas include rentschler biopharma, cdmo, bioprocess development, cgmp manufacturing, biopharmaceuticals.
Industry categories: CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Rentschler Biopharma include Cdmo — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.rentschler-biopharma.com
- Categories
- CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- rentschler biopharma, cdmo, bioprocess development, cgmp manufacturing, biopharmaceuticals
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What services does Rentschler Biopharma provide?
- They offer full-service CDMO solutions including bioprocess development, analytical development, formulation development, cGMP manufacturing, and fill & finish services, with expertise in complex biologics and difficult-to-express proteins.
- What are their manufacturing capabilities and locations?
- Facilities include expanded cleanroom space with 2,000-liter single-use bioreactors in Milford, Massachusetts, USA, and a new buffer media production plant in Laupheim, Germany, supporting cell culture-based therapeutic proteins.
- What regulatory experience do they have?
- They contributed to nearly 25% of FDA-approved biopharmaceuticals in 2023, with strict virus safety measures, process characterization, and cGMP compliance across their global operations.
Related editorial coverage
- America's Innovation Engine: Small and Mid-Sized Biotechs Drive U.S. Clinical Trials, FDA Filings
- AI Citation Gap in CDMO Capacity: Pharmaceutical Manufacturing Examples and Insights
- HHS Confirms Americans with High-Risk Ebola Exposures Will Have Access to Experimental Therapy MBP-134
- CordenPharma Expands Production Capacity with New CDMO Deal
- Novartis Ends Contract with Porton: Legal Implications and Market Impact
Explore lab tools and QA/QC resources for R&D teams.
